<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02403635</url>
  </required_header>
  <id_info>
    <org_study_id>M522101-EU24</org_study_id>
    <nct_id>NCT02403635</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction Study: ASP2151 and Midazolam</brief_title>
  <official_title>A Single-centre, Open-label Study in Healthy Men to Investigate the Effect of Repeated Oral Doses of ASP2151 on the Pharmacokinetics of Midazolam in Healthy Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maruho Europe Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maruho Europe Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CYP3A4 is involved in the metabolism of many drugs. So, it is important to assess in vivo the
      induction effect of ASP2151 on that enzyme to determine the extent of any possible drug
      interactions. The aim of this trial is to investigate the potential for interaction of
      ASP2151 with the CYP3A4 probe substrate midazolam.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of Midazolam</measure>
    <time_frame>prior to initial dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 1, Days 12, 19 and 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Peak Concentration (Tmax) of Midazolam</measure>
    <time_frame>prior to initial dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 1, Days 12, 19 and 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Concentration-Time Curve Extrapolated to Infinite Time (AUC0-∞) of Midazolam</measure>
    <time_frame>prior to initial dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 1, Days 12, 19 and 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life (t1/2) of Midazolam</measure>
    <time_frame>prior to initial dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 1, Days 12, 19 and 26</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious and Non-Serious Adverse Events</measure>
    <time_frame>Up to 32 days after the last dose</time_frame>
    <description>Refer to the result of adverse event.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Peak Plasma Concentration (Cmax) of 1-hydroxymidazolam</measure>
    <time_frame>prior to initial dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 1, Days 12, 19 and 26</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time of Peak Concentration (Tmax) of 1-hydroxymidazolam</measure>
    <time_frame>prior to initial dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 1, Days 12, 19 and 26</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area Under Concentration-Time Curve up to Last Non-zero Value (AUC0-tn) of 1-hydroxymidazolam</measure>
    <time_frame>prior to initial dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 1, Days 12, 19 and 26</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Half-life (t1/2) of 1-hydroxymidazolam</measure>
    <time_frame>prior to initial dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 1, Days 12, 19 and 26</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Trough Plasma Concentration (Ctrough) of ASP2151</measure>
    <time_frame>Days 5 to 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Peak Plasma Concentration (Cmax) of ASP2151</measure>
    <time_frame>pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time of Peak Concentration (Tmax) of ASP2151</measure>
    <time_frame>pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area Under Concentration-Time Curve Over the Dosing Interval (AUC0-tau) of ASP2151</measure>
    <time_frame>pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area Under Concentration-Time Curve Extrapolated to Infinite Time (AUC0-∞) of ASP2151</measure>
    <time_frame>pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Half-life (t1/2) of ASP2151</measure>
    <time_frame>pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Apparent Volume of Distribution (Vd/F) of ASP2151</measure>
    <time_frame>pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Apparent Total Body Clearance (CL/F) of ASP2151</measure>
    <time_frame>pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area Under Concentration-Time Curve up to Last Non-zero Value (AUC0-tn) of Midazolam</measure>
    <time_frame>prior to initial dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 1, Days 12, 19 and 26</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Apparent Volume of Distribution (Vd/F) of Midazolam</measure>
    <time_frame>prior to initial dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 1, Days 12, 19 and 26</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Apparent Total Body Clearance (CL/F) of Midazolam</measure>
    <time_frame>prior to initial dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 1, Days 12, 19 and 26</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Midazolam + ASP2151</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>400 mg ASP2151 followed by 7.5 mg midazolam</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <arm_group_label>Midazolam + ASP2151</arm_group_label>
    <other_name>Midazolam-ratiopharm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP2151</intervention_name>
    <arm_group_label>Midazolam + ASP2151</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A body mass index (Quetelet index) in the range 18.0-30.9.

          -  Sufficient intelligence to understand the nature of the trial and any hazards of
             participating in it. Ability to communicate satisfactorily with the investigator and
             to participate in, and comply with the requirements of, the entire trial.

          -  Willingness to give written consent to participate after reading the information and
             consent form, and after having the opportunity to discuss the trial with the
             investigator or his delegate.

          -  Willingness to give written consent to have data entered into The Overvolunteering
             Prevention System.

        Exclusion Criteria:

          -  Clinically relevant abnormal history, physical findings, ECG, or laboratory values at
             the pre-trial screening assessment that could interfere with the objectives of the
             trial or the safety of the volunteer.

          -  Any of the following liver function tests higher than 1.5 times the ULN at the
             screening visit: aspartate aminotransferase (AST), alanine aminotransferase (ALT),
             ALP, bilirubin, gamma glutamyl transpeptidase (gamma-GT).

          -  Platelet counts outside normal limits (129,000-346,000/µL).

          -  Presence of acute or chronic illness or history of chronic illness sufficient to
             invalidate the volunteer's participation in the trial or make it unnecessarily
             hazardous.

          -  Clinically significant impaired endocrine, thyroid, hepatic, respiratory or renal
             function, diabetes mellitus, coronary heart disease, or history of any psychotic
             mental illness.

          -  Presence or history of sleep apnoea or myasthenia gravis.

          -  History of bleeding diathesis.

          -  Surgery (eg stomach bypass) or medical condition that might affect absorption of
             medicines.

          -  Presence or history of severe adverse reaction to any drug, history of multiple drug
             allergies (multiple defined as &gt;3), or sensitivity to trial medication.

          -  Use, during the 28 days before the first dose of trial medication, of any prescription
             medicine, or any other medicine or herbal remedy (such as St John's wort) known to
             interfere with the CYP3A4, CYP2C19, CYP2C8 or CYP2C9 metabolic pathways.

          -  Use, during the 7 days before the first dose of trial medication, of any over the
             counter medicine, with the exception of paracetamol (acetaminophen).

          -  Participation in another clinical trial of a new chemical entity or a prescription
             medicine within the previous 3 months.

          -  Presence or history of drug or alcohol abuse, or intake of more than 21 units of
             alcohol weekly or more than 5 cigarettes daily.

          -  Blood pressure and heart rate in seated position at the screening examination outside
             the ranges 90-140 mm Hg systolic, 40-90 mm Hg diastolic; heart rate 40_100 beats/min.
             However, if the investigator deems the result to be not clinically significant the
             subject may be included.

          -  Possibility that the volunteer will not cooperate with the requirements of the
             protocol.

          -  Evidence of drug abuse on urine testing.

          -  Positive test for hepatitis B, hepatitis C, HIV1 or HIV2.

          -  Loss of more than 400 mL blood during the 3 months before the trial, eg as a blood
             donor.

          -  Objection by General Practitioner (GP) to volunteer entering trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joachim Dr Kempeni</last_name>
    <role>Study Director</role>
    <affiliation>Maruho Europe Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hammersmith Medicines Research Ltd</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 26, 2015</study_first_submitted>
  <study_first_submitted_qc>March 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2015</study_first_posted>
  <results_first_submitted>July 9, 2018</results_first_submitted>
  <results_first_submitted_qc>July 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 14, 2019</results_first_posted>
  <last_update_submitted>January 31, 2019</last_update_submitted>
  <last_update_submitted_qc>January 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HSV</keyword>
  <keyword>Herpes</keyword>
  <keyword>volunteers</keyword>
  <keyword>drug-drug interaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at one investigative site in United Kingdom from 18-March 2015 to 28-May 2015</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Midazolam + ASP2151</title>
          <description>400 mg ASP2151 followed by 7.5 mg midazolam
Midazolam
ASP2151</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Screening (28 Days)</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received the First Dose</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not eligible</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Midazolam + ASP2151</title>
          <description>400 mg ASP2151 followed by 7.5 mg midazolam
Midazolam
ASP2151</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.7" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak Plasma Concentration (Cmax) of Midazolam</title>
        <time_frame>prior to initial dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 1, Days 12, 19 and 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Day 1</title>
            <description>7.5 mg midazolam alone</description>
          </group>
          <group group_id="O2">
            <title>Day 12</title>
            <description>7.5 mg midazolam with 400 mg ASP2151</description>
          </group>
          <group group_id="O3">
            <title>Day 19</title>
            <description>7.5 mg midazolam alone</description>
          </group>
          <group group_id="O4">
            <title>Day 26</title>
            <description>7.5 mg midazolam alone</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration (Cmax) of Midazolam</title>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5" spread="21.2"/>
                    <measurement group_id="O2" value="23.4" spread="32.5"/>
                    <measurement group_id="O3" value="38.8" spread="23.1"/>
                    <measurement group_id="O4" value="36.8" spread="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Peak Concentration (Tmax) of Midazolam</title>
        <time_frame>prior to initial dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 1, Days 12, 19 and 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Day 1</title>
            <description>7.5 mg midazolam alone</description>
          </group>
          <group group_id="O2">
            <title>Day 12</title>
            <description>7.5 mg midazolam with 400 mg ASP2151</description>
          </group>
          <group group_id="O3">
            <title>Day 19</title>
            <description>7.5 mg midazolam alone</description>
          </group>
          <group group_id="O4">
            <title>Day 26</title>
            <description>7.5 mg midazolam alone</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Peak Concentration (Tmax) of Midazolam</title>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.50" upper_limit="1.52"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.25" upper_limit="150"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.50" upper_limit="1.50"/>
                    <measurement group_id="O4" value="0.5" lower_limit="0.28" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under Concentration-Time Curve Extrapolated to Infinite Time (AUC0-∞) of Midazolam</title>
        <time_frame>prior to initial dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 1, Days 12, 19 and 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Day 1</title>
            <description>7.5 mg midazolam alone</description>
          </group>
          <group group_id="O2">
            <title>Day 12</title>
            <description>7.5 mg midazolam with 400 mg ASP2151</description>
          </group>
          <group group_id="O3">
            <title>Day 19</title>
            <description>7.5 mg midazolam alone</description>
          </group>
          <group group_id="O4">
            <title>Day 26</title>
            <description>7.5 mg midazolam alone</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Concentration-Time Curve Extrapolated to Infinite Time (AUC0-∞) of Midazolam</title>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.1" spread="28.1"/>
                    <measurement group_id="O2" value="58" spread="29.2"/>
                    <measurement group_id="O3" value="124.4" spread="31.7"/>
                    <measurement group_id="O4" value="122.1" spread="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Half-life (t1/2) of Midazolam</title>
        <time_frame>prior to initial dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 1, Days 12, 19 and 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Day 1</title>
            <description>7.5 mg midazolam alone</description>
          </group>
          <group group_id="O2">
            <title>Day 12</title>
            <description>7.5 mg midazolam with 400 mg ASP2151</description>
          </group>
          <group group_id="O3">
            <title>Day 19</title>
            <description>7.5 mg midazolam alone</description>
          </group>
          <group group_id="O4">
            <title>Day 26</title>
            <description>7.5 mg midazolam alone</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life (t1/2) of Midazolam</title>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="37"/>
                    <measurement group_id="O2" value="3.3" spread="52.7"/>
                    <measurement group_id="O3" value="4.3" spread="43.7"/>
                    <measurement group_id="O4" value="4.1" spread="52.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious and Non-Serious Adverse Events</title>
        <description>Refer to the result of adverse event.</description>
        <time_frame>Up to 32 days after the last dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>All subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious and Non-Serious Adverse Events</title>
          <description>Refer to the result of adverse event.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Peak Plasma Concentration (Cmax) of 1-hydroxymidazolam</title>
        <time_frame>prior to initial dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 1, Days 12, 19 and 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Day 1</title>
            <description>7.5 mg midazolam alone</description>
          </group>
          <group group_id="O2">
            <title>Day 12</title>
            <description>7.5 mg midazolam with 400 mg ASP2151</description>
          </group>
          <group group_id="O3">
            <title>Day 19</title>
            <description>7.5 mg midazolam alone</description>
          </group>
          <group group_id="O4">
            <title>Day 26</title>
            <description>7.5 mg midazolam alone</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration (Cmax) of 1-hydroxymidazolam</title>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="33.2"/>
                    <measurement group_id="O2" value="15.9" spread="40.9"/>
                    <measurement group_id="O3" value="14.9" spread="35"/>
                    <measurement group_id="O4" value="14.2" spread="59.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time of Peak Concentration (Tmax) of 1-hydroxymidazolam</title>
        <time_frame>prior to initial dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 1, Days 12, 19 and 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Day 1</title>
            <description>7.5 mg midazolam alone</description>
          </group>
          <group group_id="O2">
            <title>Day 12</title>
            <description>7.5 mg midazolam with 400 mg ASP2151</description>
          </group>
          <group group_id="O3">
            <title>Day 19</title>
            <description>7.5 mg midazolam alone</description>
          </group>
          <group group_id="O4">
            <title>Day 26</title>
            <description>7.5 mg midazolam alone</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Peak Concentration (Tmax) of 1-hydroxymidazolam</title>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.50" upper_limit="1.52"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.25" upper_limit="150"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.50" upper_limit="1.50"/>
                    <measurement group_id="O4" value="0.5" lower_limit="0.28" upper_limit="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Area Under Concentration-Time Curve up to Last Non-zero Value (AUC0-tn) of 1-hydroxymidazolam</title>
        <time_frame>prior to initial dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 1, Days 12, 19 and 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Day 1</title>
            <description>7.5 mg midazolam alone</description>
          </group>
          <group group_id="O2">
            <title>Day 12</title>
            <description>7.5 mg midazolam with 400 mg ASP2151</description>
          </group>
          <group group_id="O3">
            <title>Day 19</title>
            <description>7.5 mg midazolam alone</description>
          </group>
          <group group_id="O4">
            <title>Day 26</title>
            <description>7.5 mg midazolam alone</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Concentration-Time Curve up to Last Non-zero Value (AUC0-tn) of 1-hydroxymidazolam</title>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" spread="30.3"/>
                    <measurement group_id="O2" value="39" spread="32.3"/>
                    <measurement group_id="O3" value="42.2" spread="31.3"/>
                    <measurement group_id="O4" value="40.4" spread="36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Half-life (t1/2) of 1-hydroxymidazolam</title>
        <time_frame>prior to initial dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 1, Days 12, 19 and 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Day 1</title>
            <description>7.5 mg midazolam alone</description>
          </group>
          <group group_id="O2">
            <title>Day 12</title>
            <description>7.5 mg midazolam with 400 mg ASP2151</description>
          </group>
          <group group_id="O3">
            <title>Day 19</title>
            <description>7.5 mg midazolam alone</description>
          </group>
          <group group_id="O4">
            <title>Day 26</title>
            <description>7.5 mg midazolam alone</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life (t1/2) of 1-hydroxymidazolam</title>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="39.7"/>
                    <measurement group_id="O2" value="3.1" spread="47.4"/>
                    <measurement group_id="O3" value="3.5" spread="35.4"/>
                    <measurement group_id="O4" value="3.3" spread="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Trough Plasma Concentration (Ctrough) of ASP2151</title>
        <time_frame>Days 5 to 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Day 5</title>
            <description>Day 5 pre-dose</description>
          </group>
          <group group_id="O2">
            <title>Day 6</title>
            <description>Day 6 pre-dose</description>
          </group>
          <group group_id="O3">
            <title>Day 7</title>
            <description>Day 7 pre-dose</description>
          </group>
          <group group_id="O4">
            <title>Day 8</title>
            <description>Day 8 pre-dose</description>
          </group>
          <group group_id="O5">
            <title>Day 9</title>
            <description>Day 9 pre-dose</description>
          </group>
          <group group_id="O6">
            <title>Day 10</title>
            <description>Day 10 pre-dose</description>
          </group>
          <group group_id="O7">
            <title>Day 11</title>
            <description>Day 11 pre-dose</description>
          </group>
          <group group_id="O8">
            <title>Day 12</title>
            <description>Day 12 pre-dose</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Plasma Concentration (Ctrough) of ASP2151</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="18"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277.6" spread="73.47"/>
                    <measurement group_id="O2" value="265.7" spread="64.57"/>
                    <measurement group_id="O3" value="238.9" spread="65.6"/>
                    <measurement group_id="O4" value="240.7" spread="67.73"/>
                    <measurement group_id="O5" value="223.9" spread="63.68"/>
                    <measurement group_id="O6" value="228.5" spread="67.44"/>
                    <measurement group_id="O7" value="209.7" spread="66.47"/>
                    <measurement group_id="O8" value="214.2" spread="50.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Peak Plasma Concentration (Cmax) of ASP2151</title>
        <time_frame>pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Day 12</title>
            <description>7.5 mg midazolam with 400 mg ASP2151</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration (Cmax) of ASP2151</title>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1761.4" spread="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time of Peak Concentration (Tmax) of ASP2151</title>
        <time_frame>pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Day 12</title>
            <description>7.5 mg midazolam with 400 mg ASP2151</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Peak Concentration (Tmax) of ASP2151</title>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Area Under Concentration-Time Curve Over the Dosing Interval (AUC0-tau) of ASP2151</title>
        <time_frame>pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Day 12</title>
            <description>7.5 mg midazolam with 400 mg ASP2151</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Concentration-Time Curve Over the Dosing Interval (AUC0-tau) of ASP2151</title>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17167" spread="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Area Under Concentration-Time Curve Extrapolated to Infinite Time (AUC0-∞) of ASP2151</title>
        <time_frame>pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Day 12</title>
            <description>7.5 mg midazolam with 400 mg ASP2151</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Concentration-Time Curve Extrapolated to Infinite Time (AUC0-∞) of ASP2151</title>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19334.2" spread="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Half-life (t1/2) of ASP2151</title>
        <time_frame>pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Day 12</title>
            <description>7.5 mg midazolam with 400 mg ASP2151</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life (t1/2) of ASP2151</title>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Apparent Volume of Distribution (Vd/F) of ASP2151</title>
        <time_frame>pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Day 12</title>
            <description>7.5 mg midazolam with 400 mg ASP2151</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vd/F) of ASP2151</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225.9" spread="65.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Apparent Total Body Clearance (CL/F) of ASP2151</title>
        <time_frame>pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Day 12</title>
            <description>7.5 mg midazolam with 400 mg ASP2151</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Body Clearance (CL/F) of ASP2151</title>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.61" spread="6.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Area Under Concentration-Time Curve up to Last Non-zero Value (AUC0-tn) of Midazolam</title>
        <time_frame>prior to initial dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 1, Days 12, 19 and 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Day 1</title>
            <description>7.5 mg midazolam alone</description>
          </group>
          <group group_id="O2">
            <title>Day 12</title>
            <description>7.5 mg midazolam with 400 mg ASP2151</description>
          </group>
          <group group_id="O3">
            <title>Day 19</title>
            <description>7.5 mg midazolam alone</description>
          </group>
          <group group_id="O4">
            <title>Day 26</title>
            <description>7.5 mg midazolam alone</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Concentration-Time Curve up to Last Non-zero Value (AUC0-tn) of Midazolam</title>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111" spread="28"/>
                    <measurement group_id="O2" value="56.7" spread="28.8"/>
                    <measurement group_id="O3" value="121.9" spread="30.7"/>
                    <measurement group_id="O4" value="118.9" spread="36.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Apparent Volume of Distribution (Vd/F) of Midazolam</title>
        <time_frame>prior to initial dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 1, Days 12, 19 and 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Day 1</title>
            <description>7.5 mg midazolam alone</description>
          </group>
          <group group_id="O2">
            <title>Day 12</title>
            <description>7.5 mg midazolam with 400 mg ASP2151</description>
          </group>
          <group group_id="O3">
            <title>Day 19</title>
            <description>7.5 mg midazolam alone</description>
          </group>
          <group group_id="O4">
            <title>Day 26</title>
            <description>7.5 mg midazolam alone</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vd/F) of Midazolam</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="406.5" spread="46.3"/>
                    <measurement group_id="O2" value="622" spread="47"/>
                    <measurement group_id="O3" value="370.8" spread="43.1"/>
                    <measurement group_id="O4" value="366.6" spread="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Apparent Total Body Clearance (CL/F) of Midazolam</title>
        <time_frame>prior to initial dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 h after dosing on Day 1, Days 12, 19 and 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Day 1</title>
            <description>7.5 mg midazolam alone</description>
          </group>
          <group group_id="O2">
            <title>Day 12</title>
            <description>7.5 mg midazolam with 400 mg ASP2151</description>
          </group>
          <group group_id="O3">
            <title>Day 19</title>
            <description>7.5 mg midazolam alone</description>
          </group>
          <group group_id="O4">
            <title>Day 26</title>
            <description>7.5 mg midazolam alone</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Body Clearance (CL/F) of Midazolam</title>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="444" spread="187.33"/>
                    <measurement group_id="O2" value="679.1" spread="276.5"/>
                    <measurement group_id="O3" value="401.3" spread="163.74"/>
                    <measurement group_id="O4" value="394" spread="153.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 32 days after the last dose</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Midazolam</title>
          <description>7.5 mg midazolam</description>
        </group>
        <group group_id="E2">
          <title>ASP2151 After Midazolam</title>
          <description>400 mg ASP2151 after 7.5 mg midazolam</description>
        </group>
        <group group_id="E3">
          <title>Midazolam With ASP2151</title>
          <description>7.5 mg midazolam with 400 mg ASP2151</description>
        </group>
        <group group_id="E4">
          <title>Total</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA/18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lip haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Energy increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maruho Co.,Ltd. Kyoto R&amp;D Center</name_or_title>
      <organization>Clinical Development Dept.</organization>
      <phone>+81-75-325-3255</phone>
      <email>ctinfo@mii.maruho.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

